Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550

NCT00551174 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00551174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00551174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2004
Completion date
November 30, 2008
Enrollment
781 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

post-menopausal osteoporosis